What is Phase Genomics?
Founded in 2015, Phase Genomics specializes in the development of sophisticated genomic tools that empower researchers to achieve breakthrough discoveries. The company's core competency lies in its proprietary proximity ligation technology, which facilitates high-resolution chromosome-scale genome assembly. Beyond its hardware portfolio, which includes specialized Hi-C kits for diverse biological samples, the firm provides industry-leading software solutions for metagenome assembly and analysis. By bridging the gap between complex genomic data and actionable scientific insights, Phase Genomics has established itself as an essential partner for academic, clinical, and industrial laboratories worldwide. Its multidisciplinary team of scientists and engineers remains focused on advancing the frontiers of precision medicine and infectious disease research.
How much funding has Phase Genomics raised?
Phase Genomics has raised a total of $7.4M across 4 funding rounds:
Debt
$150K
Debt
$213K
Grant
$5.5M
Other Financing Round
$1.5M
Debt (2020): $150K with participation from PPP
Debt (2021): $213K led by PPP
Grant (2022): $5.5M supported by Bill & Melinda Gates Foundation and National Institute of Allergy and Infectious Diseases
Other Financing Round (2024): $1.5M featuring Bill & Melinda Gates Foundation
Key Investors in Phase Genomics
Bill & Melinda Gates Foundation
Established in 2000 and headquartered in Seattle, Washington, The Bill & Melinda Gates Foundation is an organization that focuses on supporting individuals experiencing hunger and extreme poverty in leading healthier lives.
National Institute of Allergy and Infectious Diseases
The Vaccine Research Center is an intramural division of the NIAID, part of the NIH, dedicated to discovering and developing vaccines and antibody-based products that target infectious diseases.
PPP
Public-Private Partnership
What's next for Phase Genomics?
With the successful closure of this recent financing round, Phase Genomics is well-positioned to accelerate its product development roadmap and expand its footprint in the global genomics market. The strategic allocation of these funds will likely prioritize the scaling of its computational analysis platforms and the enhancement of its Hi-C kit manufacturing capabilities. Furthermore, the company is expected to deepen its collaborative efforts with major health organizations to address critical challenges in infectious disease surveillance and structural genomics. As the firm matures, its focus will remain on maintaining its competitive edge through continuous technological iteration and the expansion of its service-oriented business model, ensuring that its genomic architecture tools remain at the forefront of the life sciences industry.
See full Phase Genomics company page
